Rajeev Saggar Sells 21,142 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 21,142 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $791,345.06. Following the completion of the transaction, the insider owned 176,883 shares in the company, valued at $6,620,730.69. The trade was a 10.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, November 5th, Rajeev Saggar sold 71,381 shares of Liquidia stock. The shares were sold at an average price of $27.00, for a total value of $1,927,287.00.

Liquidia Stock Performance

Shares of LQDA stock opened at $39.99 on Thursday. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $40.53. The firm has a market capitalization of $3.48 billion, a P/E ratio of -27.77, a P/E/G ratio of 0.65 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The company’s fifty day moving average price is $32.41 and its two-hundred day moving average price is $25.68.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s quarterly revenue was up 1106.7% compared to the same quarter last year. On average, research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

Analysts Set New Price Targets

A number of research firms have commented on LQDA. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Needham & Company LLC increased their price target on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright lifted their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company initiated coverage on Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and an average price target of $39.67.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LQDA. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the third quarter worth about $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the third quarter valued at approximately $34,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).